Studies have shown that the combination of ICIs, such as anti‐PD‐1, anti‐PD‐L1, and anti‐CTLA‐4, in combination with CT improves survival compared to CT alone in patients with ES‐SCLC [17, 18]. The gene discussed is CTLA4; the disease is small cell lung carcinoma.